Receptor de cannabinoides
Los receptores cannabinoides son GPCR que median los efectos de los cannabinoides endógenos (endocannabinoides) y los fitocannabinoides, como los encontrados en el cannabis. Los dos tipos principales de receptores cannabinoides, CB1 y CB2, están involucrados en la regulación de una amplia gama de procesos fisiológicos, incluida la percepción del dolor, el apetito, el estado de ánimo y la función inmunitaria. Los moduladores de los receptores cannabinoides tienen potencial terapéutico en el tratamiento de afecciones como el dolor crónico, la epilepsia y la esclerosis múltiple. En CymitQuimica, ofrecemos una amplia gama de moduladores de receptores cannabinoides de alta calidad para apoyar su investigación en neurofarmacología, manejo del dolor e inmunología.
Se han encontrado 218 productos de "Receptor de cannabinoides"
Ordenar por
Pureza (%)
0
100
|
0
|
50
|
90
|
95
|
100
CB2 receptor antagonist 1
CAS:Compound 29 is a potent, CB2-selective antagonist/reverse agonist. Derivatives 23 & 24 offer antinociception; 24 activates cannabinoid/TRPV1 receptors.Fórmula:C28H47NO3Forma y color:SolidPeso molecular:445.68HU-308
CAS:HU-308, a synthetic cannabinoid analogue, is a highly selective agonist of the CB2 receptor. It demonstrates an affinity for the CB2 receptor that is over 440 times greater than its affinity for the CB1 receptor, which are predominantly found in immune cells. This compound plays a crucial role in modulating the immunosuppressive effects of the endocannabinoid system (ECS). Additionally, HU-308 possesses anti-inflammatory and neuroprotective properties, and it regulates the function of microglia. Its potential applications include research into neuroinflammation and retinal diseases.
Fórmula:C27H42O3Forma y color:SolidPeso molecular:414.62BNS808
CAS:BNS808 is an orally active, selective CB1R antagonist with an IC50 of 0.8 nM, demonstrating significant selectivity for CB2R and minimal brain penetration. It is being studied for the treatment of obesity and related metabolic complications, such as metabolic dysfunction-associated steatotic liver disease (MASLD). BNS808 reduces drug exposure to the central nervous system, enhancing safety, and minimizes drug interactions through high plasma protein binding.Fórmula:C25H20Cl3N3O3SForma y color:SolidPeso molecular:548.869CB1/2 agonist 1
Potent CB1/2 agonist 1; crosses blood-brain barrier; anti-inflammatory, analgesic; for multiple sclerosis research.Fórmula:C21H24BrFN2O2Forma y color:SolidPeso molecular:435.33CBR Agonist-2
CBR Agonist-2: CB1 receptor agonist, EC50 - 960 nM, Ki - 970 nM, useful for hCB1R-related disease research.Fórmula:C27H27FN4OForma y color:SolidPeso molecular:442.53CBR Agonist-1
CBR Agonist-1 targets CB1R and CB2R with Ki of 0.18 μM and 1.22 μM, useful for studying cannabinoid-related diseases.Fórmula:C27H27FN4OForma y color:SolidPeso molecular:442.53Taranabant
CAS:Taranabant: potent CB1 receptor inverse agonist; inhibits agonists with 0.13 nM Ki in vitro.Fórmula:C27H25ClF3N3O2Pureza:99.06% - 99.06%Forma y color:SolidPeso molecular:515.96AM8936
AM8936: potent CB1 agonist, EC50 rCB1=8.6nM/hCB1=1.4nM, Ki rat CB1=0.55nM; potential for CNS, metabolic, pain, glaucoma research.Fórmula:C25H33NO3Forma y color:SolidPeso molecular:395.53Ac-Atovaquone
CAS:Ac-Atovaquone, an ester-acetylated derivative of atovaquone, acts as a potent inhibitor of cytochrome bc1 (cytochrome bc1). This compound shows potential for use in malaria research.Fórmula:C24H21ClO4Forma y color:SolidPeso molecular:408.87HU 433
CAS:HU 433, a synthetic cannabinoid, acts as a CB2 receptor agonist and is an enantiomer of HU 308. It provides anti-inflammatory and neuroprotective effects by binding to the CB2 receptor, primarily found on immune cells, thereby modulating immune responses and inflammation. Additionally, HU 433 influences microglial signaling pathways, particularly LPS and IFNγ-mediated routes, affecting the phosphorylation of MAPKs, including ERK1/2, JNK, p38, and Akt. This compound is valuable in researching neuroinflammation and retinal diseases.Fórmula:C27H42O3Forma y color:SolidPeso molecular:414.62TM38837
CAS:CB1 antagonist 4 is an inverse agonist of cannabinoid receptor 1 (CB1) with an IC50 of 0.4 nM. It can reduce body weight, improve plasma inflammatory markers, and enhance glucose homeostasis [1].
Fórmula:C27H20Cl2F3N7OForma y color:SolidPeso molecular:586.40CB1/2 receptor-1
CAS:CB1/2 receptor-1 (compound 5.3) serves as an agonist for CB1/2 receptors and is utilized in angiogenesis research.Fórmula:C33H48O2Forma y color:SolidPeso molecular:476.73Bzo-poxizid
CAS:Bzo-poxizid is a synthetic cannabinoid and a psychoactive substance.Fórmula:C20H21N3O2Forma y color:SolidPeso molecular:335.40BAY 38-7271
CAS:BAY 38-7271: potent neuroprotective, selective CB1/CB2 agonist, Ki of 1.85 nM (CB1) & 5.96 nM (CB2).Fórmula:C20H21F3O5SPureza:98%Forma y color:SolidPeso molecular:430.44AM11638
CAS:AM11638 is an endogenous cannabinoid analogue that targets cannabinoid receptors (CB1 and CB2 receptors), exhibiting analgesic properties. It shows potential for research in neurological disorders and inflammation-related diseases.Fórmula:C27H41NO2Forma y color:SolidPeso molecular:411.62Cannabigerovarin
CAS:Cannabigerovarin (CBGV) is a compound categorized as a phytocannabinoid.Fórmula:C19H28O2Peso molecular:288.42(Rac)-Zevaquenabant
CAS:(Rac)-Zevaquenabant ((Rac)-MRI-1867, compound 6b) is a potent and selective antagonist of cannabinoid receptor type 1 (CB1R) and inducible nitric oxide synthase (iNOS), with a binding affinity (Ki) of 5.7 nM for CB1R. It holds promise as an investigative tool in liver fibrosis research due to these characteristics.Fórmula:C25H21ClF3N5O2SForma y color:SolidPeso molecular:547.98AEF0117
CAS:AEF0117 is a signaling inhibitor of CB1-SSi that inhibits cannabinoid self-administration and can be used to study cannabis withdrawal.
Fórmula:C29H40O3Pureza:99.58%Forma y color:SolidPeso molecular:436.63
